Your browser doesn't support javascript.
loading
Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen, Gui-Ling; Li, Xiao-Feng; Dai, Xia-Hong; Li, Nan; Cheng, Meng-Li; Huang, Zhen; Shen, Jian; Ge, Yu-Hua; Shen, Zhen-Wei; Deng, Yong-Qiang; Yang, Shu-Yuan; Zhao, Hui; Zhang, Na-Na; Zhang, Yi-Fei; Wei, Ling; Wu, Kai-Qi; Zhu, Meng-Fei; Peng, Cong-Gao; Jiang, Qi; Cao, Shou-Chun; Li, Yu-Hua; Zhao, Dan-Hua; Wu, Xiao-Hong; Ni, Ling; Shen, Hua-Hao; Dong, Chen; Ying, Bo; Sheng, Guo-Ping; Qin, Cheng-Feng; Gao, Hai-Nv; Li, Lan-Juan.
Afiliación
  • Chen GL; Shulan (Hangzhou) Hospital, Hangzhou, China.
  • Li XF; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
  • Dai XH; Shulan (Hangzhou) Hospital, Hangzhou, China.
  • Li N; Shulan (Hangzhou) Hospital, Hangzhou, China.
  • Cheng ML; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
  • Huang Z; Walvax Biotechnology, Kunming, China.
  • Shen J; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases/National Clinical Research Center for Infectious Diseases/Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Ge YH; Shulan (Hangzhou) Hospital, Hangzhou, China.
  • Shen ZW; Zhejiang Shuren University Shulan International Medical College, Hangzhou, China.
  • Deng YQ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
  • Yang SY; Walvax Biotechnology, Kunming, China.
  • Zhao H; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
  • Zhang NN; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
  • Zhang YF; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
  • Wei L; Suzhou Abogen Biosciences, Suzhou, China.
  • Wu KQ; Shulan (Hangzhou) Hospital, Hangzhou, China.
  • Zhu MF; Shulan (Hangzhou) Hospital, Hangzhou, China.
  • Peng CG; Shulan (Hangzhou) Hospital, Hangzhou, China.
  • Jiang Q; Shulan (Hangzhou) Hospital, Hangzhou, China.
  • Cao SC; National Institutes for Food and Drug Control, Beijing, China.
  • Li YH; National Institutes for Food and Drug Control, Beijing, China.
  • Zhao DH; National Institutes for Food and Drug Control, Beijing, China.
  • Wu XH; National Institutes for Food and Drug Control, Beijing, China.
  • Ni L; Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China.
  • Shen HH; Center for Human Disease Immuno-monitoring, Beijing Friendship Hospital, Beijing, China.
  • Dong C; Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
  • Ying B; Institute for Immunology and School of Medicine, Tsinghua University, Beijing, China.
  • Sheng GP; Center for Human Disease Immuno-monitoring, Beijing Friendship Hospital, Beijing, China.
  • Qin CF; Suzhou Abogen Biosciences, Suzhou, China.
  • Gao HN; Shulan (Hangzhou) Hospital, Hangzhou, China.
  • Li LJ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing, China.
Lancet Microbe ; 3(3): e193-e202, 2022 Mar.
Article en En | MEDLINE | ID: mdl-35098177
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Clinical_trials Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Lancet Microbe Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Tipo de estudio: Clinical_trials Límite: Adult / Humans País/Región como asunto: Asia Idioma: En Revista: Lancet Microbe Año: 2022 Tipo del documento: Article País de afiliación: China